Nilofabicin

N/A

Report date: 2025/06/30 20:00:06
NME

Base Information

Drug NameNilofabicin
Drug Alias NameEnoyl reductase inhibitors - CrystalGenomicsCG400549CG-0549CG-400549CG400549-CrystalGenomics +[7] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionEnoyl-acyl-carrier protein reductase inhibitorsFatty acid synthase inhibitors
TargetsEnoyl-acyl-carrier protein reductaseFatty acid synthase
Therapy Area/IndicationsSkin Diseases, Infectious
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlands
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCrystalgenomics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCrystalgenomics Inc
Active IndicationsN/A
Inactive IndicationsSkin Diseases, Infectious

Other Information

ATC CodeN/A
Related LinksN/A